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Tricyclic  
antidepressants, 
anticonvulsants, 
and narcotics  
all reduce  
postherpetic pain.
What measures relieve 
postherpetic neuralgia?
Evidence-based answer
Tricyclic antidepressants, gabapentin, 
and pregabalin effectively reduce  
pain (strength of recommendation  
[sOr]: a, at least 2 good-quality 
randomized controlled trials [rCTs] 
and/or meta-analyses). Opioids have 
demonstrated pain relief in 3 rCTs 
(sOr: a, consistent rCTs). Capsaicin 
and the lidocaine 5% patch relieve 
pain and decrease allodynia (sOr: B, 
recommendations from meta-analyses 
and lower-quality rCTs). 
z Evidence summary
Postherpetic neuralgia (PHN) is defined 
as pain lasting 1 to 3 months after reso-
lution of acute herpes zoster (shingles) 
rash. It occurs in approximately 10% to 
15% of patients and can cause significant 
morbidity. 
Tricyclic antidepressants  
provide effective pain relief 
Five systematic reviews have concluded 
that tricyclic antidepressants (TCAs) are 
effective treatments for PHN.1-5 Amitrip-
tyline, the best studied TCA, provides at 
least moderate pain relief in two-thirds 
of patients with a pooled number needed 
to treat (NNT) for TCAs of 2.64 (95% 
confidence interval [CI], 2.1-3.54)5 
(TABLE). 
Selective serotonin reuptake inhibi-
tors—including fluoxetine, paroxetine, 
citalopram, and sertraline—have been 
studied in a variety of neuropathic pain 
syndromes, but not for treating PHN.1 
Anticonvulsants help, too
Five systematic reviews found gabapentin 
to be effective, with a range of NNT from 
2.8 to 5.3 for as much as 50% pain re-
duction based on the visual analog score 
(VAS).2-6 Pregabalin is also effective, with 
an NNT of 4.93 (95% CI, 3.34-6.07) for 
up to 50% pain reduction.7,8 Limited data 
are available concerning the effectiveness 
of valproate.5 
A look at the role 
of narcotics
Four systematic reviews found that con-
trolled-release oxycodone reduced pain 
by 50%, based on the VAS.2-5 Another 
systematic review reported only limited 
evidence of effectiveness.6 In pooled re-
sults from systematic reviews, opioids 
decreased pain by 50% on the VAS 
(NNT=2.67; 95% CI, 2.10-3.77).6
An RCT of 76 patients demonstrated 
that morphine, with methadone as back-
up, both reduced the intensity of pain and 
relieved pain more than placebo.9 
Tramadol, a selective opioid ago-
nist, showed moderate effectiveness in 
a small RCT (N=125), with an NNT of 
4.76 (95% CI, 2.61-26.97).3,5,6 The mean 
pain intensity, degree of pain relief, and 
amount of rescue medication required 
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were all better in the tramadol group 
than the placebo group.
Evidence for topical therapy  
is limited
The anesthetic lidocaine patch 5% has 
shown efficacy in PHN with allodynia 
based on 3 RCTs of lower quality (short 
duration, recruitment of patients who had 
improved on lidocaine previously, no re-
port of baseline levels of pain); the NNT 
was 2 (95% CI, 1.4-3.3).10 A systematic 
review of these 3 RCTs concluded that 
evidence is insufficient to recommend the 
lidocaine patch as treatment for PHN.10 
Capsaicin, a topical counterirritant, 
reduced pain in fewer than 20% of pa-
tients in 2 RCTs reported in systematic 
reviews, with an NNT of 3.26 (95% CI, 
2.26-5.85).2-6 Blinding was limited in 
these studies because of the stinging as-
sociated with treatment. 
Recommendations 
A 2004 practice parameter of the Ameri-
can Academy of Neurology recommends 
TCAs (amitriptyline, nortriptyline, de-
sipramine, and maprotiline), gabapentin, 
pregabalin, opioids, topical lidocaine, 
and capsaicin to treat PHN (level of evi-
dence: A), but notes that amitriptyline 
has significant cardiac effects in the el-
derly compared with nortriptyline and 
desipramine.3 
In 2006, the European Federation of 
Neurological Societies determined that 
TCAs, gabapentin, pregabalin, and opi-
oids had established efficacy (level of evi-
dence: A), but recommended opioids as 
second-line therapy because of potential 
adverse events with long-term use.4 The 
federation’s guidelines designate cap-
saicin, tramadol, topical lidocaine, and 
valproate as drugs with lower efficacy or 
limited strength of evidence (level of evi-
What’s the NNT for drugs used to treat postherpetic neuralgia?
class drug dOsE nnt sidE EffEcts
tricyclic  
antidepressants5
Amitriptyline up to 150 mg/d 
(mean 120 mg/d)
2.64 sedation, dry mouth, 
blurred vision, 
constipation, urinary 
retention
nortriptyline up to 150 mg/d  
(mean 89 mg/d)
Desipramine up to 150 mg/d  
(mean 65-73 mg/d)
anticonvulsants3,5 Gabapentin 1800-3600 mg/d 2.8-5.3 somnolence,  
dizziness, edema,  
dry mouthPregabalin 150-600 mg/d 4.93
Opioids5 Oxycodone variable 2.67 Constipation,  
nausea, vomiting, 
sedation, dizziness,  
dependence
long-acting  
morphine/methadone
15-225 mg/d  
(morphine) 
(mean 91 mg/d for 
morphine, 15 mg/d  
for methadone)
2.67
Tramadol 100-400 mg/d  
(mean 275 mg/d)
4.76 Dependence
topicals5 Capsaicin 0.075% cream Applied 3-4 times per day 3.26 Burning skin
lidocaine 5%  
extended release patch
Max 3 patches per day 2.0 Mild skin reaction
nnT, number needed to treat.
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dence: B). Nevertheless, they recommend 
considering topical lidocaine for elderly 
patients with allodynia and small areas 
of pain.4 n 
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Both topical  
lidocaine and  
capsaicin have 
less evidence  
of efficacy  
as treatment  
for PHN.
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